Summary
This prediction ended on 26.12.17 with a price of €105.45. The prediction for Bayer AG disappointed with a performance of -13.60%. melinda has a follow-up prediction for Bayer AG where he still thinks Bayer AG is a Buy. melinda has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bayer AG | 2.457% | 2.457% | -50.769% | -47.285% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to melinda what are the pros and cons of Bayer AG for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Bayer AG diskutieren
Zulassung stivarga
26. Juni (Reuters) - Die Bayer AG: Hält die Zulassung von Stivarga in Japan für eine Second-Line - Behandlung des hepatozellulären Karzinoms.
(Laufzeit überschritten)